MHRA publishes plans to reform medicines regulatory systems for rare diseases
Existing medicines regulatory processes do not consider the challenges that accompany treatment development for rare diseases. The regulatory body for medicines in the UK, the MHRA, has recognised this and is planning a major change by proposing a new framework for rare diseases. We welcome their report, […]
MHRA publishes plans to reform medicines regulatory systems for rare diseases Read More »